Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

9 clinical trials · Sponsor

Sort:Newest first Oldest first

◉ Watch Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

Record	Firm	Date
Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease (NCT07452822)	Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	2026-02-20
Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma (NCT07369492)	Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	2026-01-01
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT07368270)	Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	2026-01-01
Evaluate the Distribution and Dynamic Behavior of Nuclide Labeled TH-SC01 Cells in Vivo in Patients With Radiation Proctitis (NCT06925607)	Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	2025-04-01
Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease (NCT06925594)	Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	2025-03-20
Umbilical-Cord-Derived Mesenchymal Stem Cells Injection for Chronic Radiation Proctitis (NCT06438809)	Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	2024-05-24
Evaluate the Distribution and Dynamic Behavior of TH-SC01 Cells in Vivo in Patients With Perianal Fistula (NCT06429241)	Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	2024-04-08
The Purpose of This Study is to Evaluate the Safety and Efficacy of Human TH-SC01 Cell Injection in the Treatment of Complex Perianal Fistula (NCT05677672)	Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	2022-12-30
A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease (NCT05626023)	Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	2022-01-30

Track Jiangsu Topcel-KH Pharmaceutical Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.